948264.fig.003a
(a)
948264.fig.003b
(b)
948264.fig.003c
(c)
948264.fig.003d
(d)
948264.fig.003e
(e)
948264.fig.003f
(f)
Figure 3: Cytoplasmic delocalization with high expression of beta-catenin (a)–(d) and cytoplasmic delocalization of beta-catenin with immunostaining absence of marker (e)-(f). Cytoplasmic delocalization with high expression of beta-catenin has been prevalently observed in OSCCs/OPSCCS of the tongue, trigonous, gingival mucosa, jaw, and in the tumors sited on the floor of the mouth, on the alveolar ridge, and, finally, in the multifocal neoplasias ( ) (a). This immunohistochemical pattern was also observed in undifferentiated carcinomas ( ) (b), with clinical history of lymph nodal metastases (N+) ( ) (c), and with worse prognosis ( ) (d). Cytoplasmic delocalization with loss of beta-catenin was, generally, reported in oropharyngeal carcinomas and cheek cancer ( ) (e), in Italian patients ( ) (f).